HTuO Biosceinces Inc., 2110 East 6th Avenue, Vancouver, BC, V5N 1R1, Canada.
Graduate School of Integrated Sciences for Life, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima, Hiroshima, 739-8530, Japan.
Future Med Chem. 2022 Oct;14(19):1349-1360. doi: 10.4155/fmc-2022-0134. Epub 2022 Sep 8.
The 17-membered polyketide, lankacidin C, exhibits considerable antitumor activity as a microtubule stabilizer by binding to the paclitaxel binding site. Esterification of the C-7/C-13 hydroxyl in lankacidin C was performed with acetyl, cinnamoyl and hydrocinnamoyl groups and their antitumor activity was assessed to improve the cytotoxicity of lankacidins through bioinspired computational design. Compared with the cytotoxicity of parent lankacidin C against the HeLa cell line, 13--cinnamoyl-lankacidin C demonstrated sevenfold higher cytotoxicity. Furthermore, 7,13-di--cinnamoyl-lankacidin C exhibited considerable antitumor activity against three tested cell lines. C13-esterification by a cinnamoyl group dramatically improved antitumor activity, in agreement with computational predictions. This finding provides a potential substrate for next-generation lankacidin derivatives with significant antitumor activity.
十七元聚酮化合物 lankacidin C 通过与紫杉醇结合位点结合作为微管稳定剂表现出相当大的抗肿瘤活性。通过乙酰化、肉桂酰化和氢化肉桂酰化对 lankacidin C 的 C-7/C-13 羟基进行酯化,并通过生物启发的计算设计评估其抗肿瘤活性,以提高 lankacidins 的细胞毒性。与母体 lankacidin C 对 HeLa 细胞系的细胞毒性相比,13--肉桂酰基-lankacidin C 的细胞毒性高 7 倍。此外,7,13-二--肉桂酰基-lankacidin C 对三种测试细胞系表现出相当大的抗肿瘤活性。肉桂酰基在 C13 位的酯化极大地提高了抗肿瘤活性,与计算预测一致。这一发现为具有显著抗肿瘤活性的下一代 lankacidin 衍生物提供了一个潜在的底物。